Cisplatin Shortage Deemed Over Free

Yesterday, the FDA announced that the supply of cisplatin now exceeds demand, bringing an end to a national shortage that has plagued cancer treatment providers since it was declared on February 10, 2023. To that end, the FDA worked closely with five cancer drug manufacturers to increase manufacturing capacity; helped a sixth company that had stopped producing an approved product to reenter the market; and temporarily exercised discretion in not enforcing importation requirements to meet patient needs while ensuring that manufacturing sites were thoroughly evaluated to protect the health and safety of patients in the United States. Seven manufacturers are now producing the drug for the U.S. market.